vs
Side-by-side financial comparison of CME Group (CME) and Dexcom (DXCM). Click either name above to swap in a different company.
CME Group is the larger business by last-quarter revenue ($1.9B vs $1.3B, roughly 1.5× Dexcom). Dexcom runs the higher net margin — 21.2% vs 0.1%, a 21.2% gap on every dollar of revenue. On growth, Dexcom posted the faster year-over-year revenue change (21.6% vs 14.5%). Over the past eight quarters, Dexcom's revenue compounded faster (12.0% CAGR vs 10.8%).
CME Group Inc. is an American financial services company based in Chicago, Illinois. It operates financial derivatives exchanges, including the Chicago Mercantile Exchange (CME), the Chicago Board of Trade (CBOT), the New York Mercantile Exchange (NYMEX), and the Commodity Exchange (COMEX). The company owns 27% of S&P Dow Jones Indices. It is the world's largest operator of financial derivatives exchanges. Its exchanges are platforms for trading in agricultural products, currencies, energy, i...
Dexcom, Inc. is an American multinational healthcare company that develops, manufactures, produces and distributes a line of continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with global headquarters and R&D center in San Diego, California, U.S.A. and manufacturing facilities in Mesa, Arizona, U.S.A.; Batu Kawan, Malaysia and Athenry, County Galway, Ireland.
CME vs DXCM — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.9B | $1.3B |
| Net Profit | $1.2M | $267.3M |
| Gross Margin | — | 62.9% |
| Operating Margin | 0.1% | 25.6% |
| Net Margin | 0.1% | 21.2% |
| Revenue YoY | 14.5% | 21.6% |
| Net Profit YoY | 20.7% | 153.6% |
| EPS (diluted) | — | $0.67 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.9B | $1.3B | ||
| Q4 25 | $1.6B | $1.3B | ||
| Q3 25 | $1.5B | $1.2B | ||
| Q2 25 | $1.7B | $1.2B | ||
| Q1 25 | $1.6B | $1.0B | ||
| Q4 24 | $1.5B | $1.1B | ||
| Q3 24 | $1.6B | $994.2M | ||
| Q2 24 | $1.5B | $1.0B |
| Q1 26 | $1.2M | $267.3M | ||
| Q4 25 | $1.2B | $267.3M | ||
| Q3 25 | $908.0M | $283.8M | ||
| Q2 25 | $1.0B | $179.8M | ||
| Q1 25 | $956.2M | $105.4M | ||
| Q4 24 | $874.6M | $151.7M | ||
| Q3 24 | $912.8M | $134.6M | ||
| Q2 24 | $883.2M | $143.5M |
| Q1 26 | — | 62.9% | ||
| Q4 25 | — | 62.9% | ||
| Q3 25 | — | 60.5% | ||
| Q2 25 | — | 59.5% | ||
| Q1 25 | — | 56.9% | ||
| Q4 24 | — | 58.9% | ||
| Q3 24 | — | 59.7% | ||
| Q2 24 | — | 62.4% |
| Q1 26 | 0.1% | 25.6% | ||
| Q4 25 | 61.8% | 25.6% | ||
| Q3 25 | 63.3% | 20.1% | ||
| Q2 25 | 66.7% | 18.4% | ||
| Q1 25 | 67.5% | 12.9% | ||
| Q4 24 | 62.1% | 17.0% | ||
| Q3 24 | 64.6% | 15.3% | ||
| Q2 24 | 65.3% | 15.7% |
| Q1 26 | 0.1% | 21.2% | ||
| Q4 25 | 71.7% | 21.2% | ||
| Q3 25 | 59.1% | 23.5% | ||
| Q2 25 | 60.6% | 15.5% | ||
| Q1 25 | 58.2% | 10.2% | ||
| Q4 24 | 57.3% | 13.6% | ||
| Q3 24 | 57.6% | 13.5% | ||
| Q2 24 | 57.6% | 14.3% |
| Q1 26 | — | $0.67 | ||
| Q4 25 | $3.24 | $0.67 | ||
| Q3 25 | $2.49 | $0.70 | ||
| Q2 25 | $2.81 | $0.45 | ||
| Q1 25 | $2.62 | $0.27 | ||
| Q4 24 | $2.40 | $0.37 | ||
| Q3 24 | $2.50 | $0.34 | ||
| Q2 24 | $2.42 | $0.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.4B | $917.7M |
| Total DebtLower is stronger | $3.4B | — |
| Stockholders' EquityBook value | — | $2.7B |
| Total Assets | $202.0B | $6.3B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $2.4B | $917.7M | ||
| Q4 25 | $4.5B | $917.7M | ||
| Q3 25 | $2.6B | $1.8B | ||
| Q2 25 | $2.1B | $1.2B | ||
| Q1 25 | $1.5B | $904.9M | ||
| Q4 24 | $3.0B | $606.1M | ||
| Q3 24 | $2.4B | $621.2M | ||
| Q2 24 | $1.9B | $939.2M |
| Q1 26 | $3.4B | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $2.7B | ||
| Q4 25 | $28.7B | $2.7B | ||
| Q3 25 | $28.2B | $2.7B | ||
| Q2 25 | $27.7B | $2.6B | ||
| Q1 25 | $27.0B | $2.3B | ||
| Q4 24 | $26.5B | $2.1B | ||
| Q3 24 | $28.2B | $2.0B | ||
| Q2 24 | $27.6B | $2.4B |
| Q1 26 | $202.0B | $6.3B | ||
| Q4 25 | $198.4B | $6.3B | ||
| Q3 25 | $187.1B | $7.5B | ||
| Q2 25 | $179.9B | $7.3B | ||
| Q1 25 | $157.8B | $6.8B | ||
| Q4 24 | $137.4B | $6.5B | ||
| Q3 24 | $137.8B | $6.4B | ||
| Q2 24 | $123.4B | $6.8B |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
